Due to the fact that the use of the patented substance is subject to the patentee’s consent, unauthorized third parties engaging in the manufacturing of similar products risk patent infringement suits. The granting of pharmaceutical patents may therefore entail considerable challenges for generic drugs producers. A patent granted on the pharmaceutical substance is therefore usually considered to be a more serious obstacle for generic producers than a patent granted for the process of making or using a drug.